Bioprocess Market Watch. November 2026 edition for European suppliers
So far, ClinicalTrials.gov counts 4 industry biologics trials started in Europe in October 2026. The count is provisional, because many studies are registered weeks after they start. This edition covers open data up to 31 October 2026, or the latest month published, on trials, medicine approvals, equipment imports into the EU and registrations in Brazil, for anyone running marketing or sales at a European bioprocess supplier.
In October 2026, 64 industry biologics trials started worldwide, 24 in the United States, 20 in Asia and 4 in Europe. In the last twelve months, only March had more worldwide, with 74. The EMA authorised 1 medicine and the FDA approved 2. The FDA also issued 14 CGMP warning letters. EU import data run to August 2026.
Europe's 4 is provisional and the lowest figure of the twelve months. Many studies reach ClinicalTrials.gov weeks after they start, so the latest month usually rises. That is what happened to September. In the October edition, with data downloaded on 1 November 2026, September had 10 trials in Europe, and the 15 November download gives it 13.
4
Biologics trials started in Europe
Previous month 13, change -9
64
Biologics trials started worldwide
Previous month 62, change +2
24
Biologics trials started in the United States
Previous month 22, change +2
20
Biologics trials started in Asia
Previous month 18, change +2
1
Medicines authorised by the EMA
Previous month 7, change -6
2
FDA approvals, CDER and CBER
Previous month 10, change -8
14
FDA CGMP warning letters
Previous month 13, change +1
See the data as a table
Indicators for October 2026 compared with September, counts of official records downloaded on 15 November 2026. October figures may still change.
Indicator
Month
Previous month
Change
Biologics trials started in Europe
Month
4
Previous month
13
Change
-9
Biologics trials started worldwide
Month
64
Previous month
62
Change
+2
Biologics trials started in the United States
Month
24
Previous month
22
Change
+2
Biologics trials started in Asia
Month
20
Previous month
18
Change
+2
Medicines authorised by the EMA
Month
1
Previous month
7
Change
-6
FDA approvals, CDER and CBER
Month
2
Previous month
10
Change
-8
FDA CGMP warning letters
Month
14
Previous month
13
Change
+1
EMA authorisations and FDA approvals from May to October 2026
In October 2026, the EMA authorised 1 human medicine through the centralised procedure, and it was not a biosimilar. The FDA approved 2, both novel drugs from CDER, while CBER approved no new licenses. Over the six months in the chart, the EMA peaks in July with 8, and the FDA in August and September with 10.
A month with 1 or 2 approvals does not signal a change of direction. The EMA authorises in batches, and the series has 14 medicines in November 2025 and only 1 in December. Recent CBER licenses may not be on the FDA page yet. And the EMA table only flags biosimilars, so it does not say whether October's medicine is a biologic.
EMA authorisations and FDA approvals to October 2026, November edition
EMA
FDA
EMA authorisations and FDA approvals to October 2026, November edition
How many biologics trials started in Spain in October 2026?
ClinicalTrials.gov counts 1 industry trial with at least one biological intervention and a site in Spain, against 3 in September. The figure is provisional, from the database as of 13 November 2026, and may rise once studies that have already started are registered. A study with sites in Spain and other countries counts in each country.
Where industry biologics trials started in October 2026
By territory, the United States had 24 new trials in October 2026, Asia 20, Europe 4 and Latin America 1. The count covers industry-sponsored interventional studies with at least one biological intervention, by the start month recorded on ClinicalTrials.gov. A study with sites in several countries counts in each country and once in each territory.
In the country breakdown, Switzerland has 2, and Germany and Spain 1 each. France, Italy, the United Kingdom, the Netherlands, Belgium and Poland have none yet. The European total also includes countries outside the breakdown, and one study can count in more than one country, so the 4 do not necessarily come from those three.
For a supplier, behind each new trial is a sponsor that needs clinical trial material, often made in its own pilot plant or at a CDMO. The count understates the total, because many monoclonal antibody trials are registered as DRUG rather than BIOLOGICAL. For Europe, look at all twelve months, which range from 6 to 17 outside October.
Biologics trials started in October 2026 by territory, November edition
Biologics trials started in October 2026 by territory, November edition
Territory
Trials started
Europe
4
United States
24
Asia
20
Latin America
1
Interventional industry trials with at least one biological intervention started in October 2026, by territory, from the database as of 13 November 2026. Provisional count. Source ClinicalTrials.gov, API v2
Imports under 8419.89 into the 27 EU member states in August 2026
Eurostat publishes with a lag, and August 2026 is the latest month with data for all 27 member states, updated on 13 November. That month, the 27 imported 162,202 thousand euros under subheading 8419.89, against 194,616 in July (-16.7%). Germany imported 41,098 thousand euros, the Netherlands 15,541, France 13,476 and Spain 11,070, fourth on the list.
Subheading 8419.89 covers many machines for treating materials through a change of temperature, and bioreactors and fermenters are only part of it. It counts what enters each state from anywhere, other EU states included, in current euros. Eurostat may still revise August, and one month is not a trend.
Imports under subheading 8419.89 in August 2026, November edition
Imports under subheading 8419.89 in August 2026, November edition
Member state
Thousand euros
Germany
41,098
Netherlands
15,541
France
13,476
Spain
11,070
Austria
9,796
Ireland
8,485
Hungary
8,393
Italy
6,980
The eight member states with the highest imports under subheading 8419.89 in August 2026, the latest month with data for all 27, in thousand euros. Source Eurostat, Comext DS-045409
Why does Europe show only 4 trials in October 2026?
Because the count is still incomplete. October is the last month in this edition and many studies are registered weeks after they start. September shows how this works, with 10 trials in Europe in the 1 November 2026 download and 13 in the 15 November one. The 4 is the lowest figure of the twelve months, but it does not yet point to a decline.
What the data show for Asia and Latin America in October 2026
In Asia, 20 biologics trials started in October 2026, and 15 of them have a site in China. South Korea has 3, Japan 2 and India 1. Latin America had 1, with a site in Colombia, while Brazil, Mexico, Argentina and Chile have none yet.
In Brazil, ANVISA registered 7 biological medicines in October and 6 in September, and the highest month in the series is April 2026, with 20. In Japan, the PMDA list has 135 new drug entries for FY2024, from April 2024 to March 2025. FY2025, still partial, has 119 entries up to February 2026.
Asia here means only Japan, China, India and South Korea, and Latin America means Brazil, Mexico, Argentina, Colombia and Chile. Studies that appear only in a national registry are left out. The ANVISA file of 13 November has no registration date, so the process completion date is used. PMDA entries include new indications and doses and serve only as context.
Do these counts measure demand for bioprocess equipment?
No. The figures are counts of official records, such as a study starting, a medicine being authorised or an FDA letter, plus the value imported under a subheading that covers far more than bioreactors. They show where the sector is moving, but they do not say how much bioprocess equipment is bought, in units or in euros. That is why there are no market sizes or forecasts here.
What a European bioprocess supplier can do with the October figures
For the coming quarter, these figures do not call for big changes. The United States, with 24 new trials, and Asia, with 20, stay within their range of the past year, so if you already sell there, keep up the effort. In Europe, check each country's twelve months in this edition's CSV file before cutting back, because the 4 is provisional. In Spain, with 1 trial in October and 3 in September, one month says little.
With trial sponsors, talk about clinical trial material, scale-up and GMP documentation. For the United States, make sure your English content answers technical questions so buyers do not need to call. For Asia, decide the language with your distributor in each country. Germany was the largest importer under subheading 8419.89 in August, but the subheading covers far more than bioreactors. If you want to sell there, it helps to have your key pages in German.
Make sure your website and datasheets state the scale each system works at and the GMP documentation that comes with it, and share them with your distributors. If you are going to a trade show before the next edition, bring these figures with their download date. crida studio does marketing for bioprocess equipment makers and life science companies, and its founder ran marketing at a European manufacturer for three and a half years.
Is your market or segment missing from this edition? Tell us which one, and we will consider adding it next month or preparing it just for you.
Compared with September, trials rise from 62 to 64 worldwide (+3.2%), from 22 to 24 in the United States (+9.1%) and from 18 to 20 in Asia (+11.1%). Europe goes from 13 to 4, and Latin America and Spain from 3 to 1, with October still incomplete. The September figures come from the 15 November download, and some no longer match those in the October edition.
The EMA goes from 7 authorisations to 1 and the FDA from 10 approvals to 2. CGMP warning letters rise from 13 to 14 (+7.7%), and October may still add more. Imports under subheading 8419.89 fall 16.7% from July to August. In the chart, worldwide trials range from a low of 39 in July to a high of 74 in March, and October, at 64, is the second-highest month.
Biologics trials started worldwide to October 2026, November edition
Biologics trials started worldwide to October 2026, November edition
Month
Trials
Nov 2025
42
Dec 2025
62
Jan 2026
57
Feb 2026
56
Mar 2026
74
Apr 2026
54
May 2026
49
Jun 2026
58
Jul 2026
39
Aug 2026
44
Sep 2026
62
Oct 2026
64
Interventional industry trials with at least one biological intervention started worldwide each month, November 2025 to October 2026. October is still provisional. Source ClinicalTrials.gov, API v2
Where can I download the data and how were they counted?
The figures can be downloaded as CSV and JSON from this page, with the source and download date of each value. Scripts read the eight official sources with the same filters every month, without estimates. The method section at the end of the page gives the exact query and the limits of each source.
Sources, queries and limits of this edition
All sources were downloaded on 15 November 2026. The data run to 31 October 2026, except Eurostat, which runs to August, and the PMDA list, which runs to February 2026. These are counts of official records and, for Eurostat, import values, with no estimates of our own. They do not measure orders or sales of bioprocess equipment. The latest month of each series can still move. Below are the exact query and limits for each source.
Want this analysis applied to your target markets?
All the data in this edition are public and downloadable. If you want the same analysis for your product portfolio, get in touch and we will prepare it with you in a thirty-minute session.